Nuevolution A/S Appoints Professor Mark C. Genovese as Advisor
News Nov 21, 2015
Nuevolution has announced that Dr. Mark Genovese has joined as Scientific Advisor. Mark brings a vast knowledge and expertise within the field of inflammatory diseases to Nuevolution as well as a profound understanding of pre-clinical and clinical research, supporting the commercial value of Nuevolution’s program pipeline.
Dr. Genovese serves as a Professor of Medicine and is Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center. He established a clinical research program at Stanford University that is focused on bench-to-bedside translational medicine in autoimmune diseases and has designed and participated in many trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis.
“We are happy to have initiated our collaboration with Mark, who is a leader in the field of clinical immunology, and that he has accepted to join our Advisory Panel, said Thomas Franch, CSO of Nuevolution. “We are certain that Mark’s expertise will help us to accelerate our immunology projects further to meet our ambitions of providing novel treatment options for inflammatory diseases”.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE